Lexaria completes dosing in five-week oral semaglutide study
LEXX•Lexaria Bioscience said dosing finished on schedule in its five-week study comparing DehydraTECH-semaglutide tablets and capsules with Novo’s commercial Wegovy tablets.
1. Study dosing completed
The study, GLP-1-H26-7, assesses safety, tolerability and drug absorption. It is the first human trial of Lexaria’s DehydraTECH-semaglutide tablet formulation; results will be reported after laboratory analysis, data review and quality checks.




